AstraZeneca: Phase III lung cancer study results delayed
(CercleFinance.com) - The final analysis of a keenly awaited late-stage trial on AstraZeneca's immunotherapy Imfinzi in lung cancer is now expected in the second half of 2018, the group said on Monday.
The final results of the Phase III trial of Imfinzi in combination with tremelimumab in patients with stage 4 non-small cell lung cancer (NSCLC) was originally due in the first half, the drugmaker said.
Despite this, its shares do not seem to be impacted by this news, adding 0.4% at 4,805 pence in London this morning.
Copyright (c) 2018 CercleFinance.com. All rights reserved.
The final results of the Phase III trial of Imfinzi in combination with tremelimumab in patients with stage 4 non-small cell lung cancer (NSCLC) was originally due in the first half, the drugmaker said.
Despite this, its shares do not seem to be impacted by this news, adding 0.4% at 4,805 pence in London this morning.
Copyright (c) 2018 CercleFinance.com. All rights reserved.